The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) securities during the period of October 31, 2023 to July 1, 2024, inclusive (“the Class Period”). Investors have until October 15, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

[Click here to learn more about the class action]

The Ardelyx class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that Ardelyx had not reached a firm decision concerning whether or not to apply to include XPHOZAH in Transitional Drug Add-on Payment Adjustment (“TDAPA”), a program to pay for new ESRD-related therapies not yet in the ESRD Prospective Payment System (“ESRD PPS”) bundle, and could not, in fact, decide whether or not to submit such an application to the Centers for Medicare and Medicaid Services (“CMS”) until after defendants first reviewed CMS’s proposed calendar year 2025 ESRD PPS rule, which was only issued on June 27, 2024.

If you purchased or otherwise acquired Ardelyx securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240926352261/en/